Evaluation of F-18 fluorodeoxyglucose positron emission tomography for the diagnosis of Alzheimer’s disease (2014)

Evaluation of F-18 fluorodeoxyglucose positron emission tomography for the diagnosis of Alzheimer’s disease (2014)

The Department of Health engaged HealthConsult to undertake an evaluation of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) for the diagnosis of Alzheimer’s disease. The evaluation included a review of the clinical evidence for the diagnostic accuracy, safety and effectiveness of FDG-PET for people with suspected Alzheimer’s disease in whom prior tests are inconclusive. The cost-effectiveness of the service and the expected utilisation and financial implications for the Medicare Benefits Schedule (MBS) were also assessed. The evaluation was considered by the Medical Services Advisory Committee (MSAC) when it formulated its advice to the Minister for Health on whether the service should be publicly funded. The project commenced in October 2014 and was completed in December 2014.